Li YF - Search Results

1

Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study.

Wang HM, Zhang CY, Peng KC, Chen ZX, Su JW, Li YF, Li WF, Gao QY, Zhang SL, Chen YQ, Zhou Q, Xu C, Xu CR, Wang Z, Su J, Yan HH, Zhang XC, Chen HJ, Wu YL, Yang JJ. Wang HM, et al. Among authors: li wf, li yf. Cell Rep Med. 2023 Feb 21;4(2):100911. doi: 10.1016/j.xcrm.2022.100911. Epub 2023 Jan 18. Cell Rep Med. 2023. PMID: 36657446 Free PMC article.

2

Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies.

Dong ZY, Zhang C, Li YF, Su J, Xie Z, Liu SY, Yan LX, Chen ZH, Yang XN, Lin JT, Tu HY, Yang JJ, Zhou Q, Sun YL, Zhong WZ, Wu YL. Dong ZY, et al. Among authors: li yf. J Thorac Oncol. 2018 Jan;13(1):85-96. doi: 10.1016/j.jtho.2017.10.020. Epub 2017 Nov 7. J Thorac Oncol. 2018. PMID: 29127022 Free article.

3

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer.

Dong ZY, Zhang JT, Liu SY, Su J, Zhang C, Xie Z, Zhou Q, Tu HY, Xu CR, Yan LX, Li YF, Zhong WZ, Wu YL. Dong ZY, et al. Among authors: li yf. Oncoimmunology. 2017 Jul 26;6(11):e1356145. doi: 10.1080/2162402X.2017.1356145. eCollection 2017. Oncoimmunology. 2017. PMID: 29147605 Free PMC article.

4

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation.

Su S, Dong ZY, Xie Z, Yan LX, Li YF, Su J, Liu SY, Yin K, Chen RL, Huang SM, Chen ZH, Yang JJ, Tu HY, Zhou Q, Zhong WZ, Zhang XC, Wu YL. Su S, et al. Among authors: li yf. J Thorac Oncol. 2018 Nov;13(11):1668-1675. doi: 10.1016/j.jtho.2018.07.016. Epub 2018 Jul 26. J Thorac Oncol. 2018. PMID: 30056164 Free article.

5

Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.

Liu SY, Dong ZY, Wu SP, Xie Z, Yan LX, Li YF, Yan HH, Su J, Yang JJ, Zhou Q, Zhong WZ, Tu HY, Yang XN, Zhang XC, Wu YL. Liu SY, et al. Among authors: li yf. Lung Cancer. 2018 Nov;125:86-92. doi: 10.1016/j.lungcan.2018.09.010. Epub 2018 Sep 14. Lung Cancer. 2018. PMID: 30429043

6

Response to Icotinib Plus Chemotherapy in Pulmonary Atypical Carcinoid Harboring the EGFR L858R Mutation: A Brief Report.

Chen YQ, Li YF, Zhang CY, Zhang SL, Lv ZY, Dong S, Chen HJ, Zhang XC, Wu YL, Yang JJ. Chen YQ, et al. Among authors: li yf. JTO Clin Res Rep. 2021 Nov 19;2(12):100258. doi: 10.1016/j.jtocrr.2021.100258. eCollection 2021 Dec. JTO Clin Res Rep. 2021. PMID: 34917992 Free PMC article.

7

Dynamic ¹⁸ F-FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non-small cell lung cancer.

Chen ZY, Fu R, Tan XY, Yan LX, Tang WF, Qiu ZB, Qi YF, Li YF, Hou QY, Wu YL, Zhong WZ, Jiang BY. Chen ZY, et al. Among authors: li yf. Thorac Cancer. 2022 Sep;13(17):2524-2531. doi: 10.1111/1759-7714.14562. Epub 2022 Jul 12. Thorac Cancer. 2022. PMID: 35822254 Free PMC article.

8

A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.

Zhang CY, Sun H, Su JW, Chen YQ, Zhang SL, Zheng MY, Li YF, Huang J, Zhang C, Tai ZX, Cai M, Zhang XC, Su J, Xu CR, Yan HH, Chen HJ, Wu YL, Yang JJ. Zhang CY, et al. Among authors: li yf. Lung Cancer. 2023 Jan;175:68-78. doi: 10.1016/j.lungcan.2022.11.016. Epub 2022 Nov 25. Lung Cancer. 2023. PMID: 36473332 Free article.

9

The predictive value of YAP-1 and POU2F3 for the efficacy of immuno-chemotherapy in extensive-stage SCLC patients.

Chen YQ, Gao LL, Kong LC, Guan XH, Yang H, Li YF, Lv ZY, Zhang XC, Liang HY, Chen HJ, Wu YL, Huang J, Yang JJ. Chen YQ, et al. Among authors: li yf. Cancer Treat Res Commun. 2023;35:100684. doi: 10.1016/j.ctarc.2023.100684. Epub 2023 Jan 25. Cancer Treat Res Commun. 2023. PMID: 36716535 Free article.

10

Pathological characteristics and tumour immune microenvironment of lung malignancies with RET rearrangement.

Gao QY, Xiao FM, Lin XC, Chen YQ, Li YF, Lu C, Su JW, Tan QQ, Zhang CY, Yang J, Wu YL, Chen HJ, Yang JJ. Gao QY, et al. Among authors: li yf. Cancer Treat Res Commun. 2023;35:100707. doi: 10.1016/j.ctarc.2023.100707. Epub 2023 Apr 20. Cancer Treat Res Commun. 2023. PMID: 37121144 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,169 results

Search Page